Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs State Street SPDR S&P Biotech ETF — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $28.57 (market cap $157.51B), while State Street SPDR S&P Biotech ETF trades at $159.44. The key difference: Banco Bilbao Vizcaya Argentaria SA pays a 3.8% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| BBVA | XBI | |
|---|---|---|
Market Cap | $157.51B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $28.50 | $164.28 |
52-Week Low | $17.96 | $86.92 |
Dividend Yield | 3.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $28.35 with a bullish technical outlook, supported by moving averages and a strong ADX trend indicator. The company reported robust Q2 2026 earnings, beating EPS estimates with $0.63 actual versus $0.59 expected, driven by loan growth and a new $2.3 billion share buyback announcement. Revenue reached $39.42 billion in 2025, with net income of $10.51 billion and a rising profit margin of 26.66%.
Outlook remains positive with analyst consensus leaning buy (53.85%) and a projected revenue increase to $42.5 billion in 2026. Key risks include regulatory probes in Spain and volatile cash flow trends, but strong profitability and institutional support suggest upside potential for investors seeking European bank exposure.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
